CLINICAL_TRIALS
trial_result
· 2023-11-13
Clinical Trial Update: Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD [Phase 3]
Summary
Phase 3 trial comparing biosimilar Xlucane to Lucentis in neovascular age-related macular degeneration has completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Xbrane Biopharma AB | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2023-11-13